Ascendis Pharma A/S (ASND) announced positive topline data from a Phase 3 trial of TransCon CNP (navepegritide) for children with achondroplasia, a genetic disorder causing dwarfism. The investigational drug demonstrated significant improvement in growth velocity compared to placebo, leading to a potential FDA application in the first quarter of 2025.